The role of anticoagulant and thrombolitic in treatment of COVID patients
Phase 3
Recruiting
- Conditions
- COVID 19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200515047456N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
COVID patients with P/F ratio less than 100
D.dimer more than 3000 without response to other medications
Exclusion Criteria
Active bleeding
Platelet less than 30000
Without any contraindication for thrombolytic therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improve of oxygenasion. Timepoint: From first to 6th days of study. Method of measurement: Arterial blood gas.;Improve SOFA score. Timepoint: From first to 6th days of study. Method of measurement: Questionnaire.;Improve compliance. Timepoint: From first to 6th days of study. Method of measurement: Ventilator parameter.;Decrease d.Dimer level. Timepoint: From first to 6th days of study. Method of measurement: Blood sample.
- Secondary Outcome Measures
Name Time Method